News

In this new age, Clinical research is experiencing a soft but mighty revolution, powered by the introduction of open-source ...
NEW YORK, NY, UNITED STATES, May 29, 2025 /EINPresswire.com/ -- CCRPS, internationally recognized as a leader in clinical ...
Prothena Corporation plc's phase 3 trial failure in AL Amyloidosis was a setback, but Alzheimer's & Parkinson's data could ...
Magic mushrooms” may conjure images of people in the 1960s using hallucinogenic drugs to launch journeys of self-discovery.
The HonorHealth Research Institute has initiated an international clinical trial in Arizona, aiming to test new cell therapy for melanoma treatment.
NeuroPace Inc. (NASDAQ:NPCE) saw its stock nosedive by 36.1% today after announcing that its NAUTILUS clinical trial failed ...
Contemporary Clinical trials, 33: 5-11 (2012) Zheng Su, PhD, is Senior Statistical Scientist at Genentech Inc. and Editor-in-Chief of Contemporary Clinical Trials, which provides a platform for ...
After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...
No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...
NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.
PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...
Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...